Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
86,100
-
Share change
-
-80,892,362
-
Total reported value
-
$425,000
-
Price per share
-
$4.94
-
Number of holders
-
1
-
Value change
-
-$245,915,234
-
Number of sells
-
163
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2025
As of 31 Mar 2025,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
86,100 shares.
The largest 1 holders included
DekaBank Deutsche Girozentrale.
This page lists
1
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.